EUVIMEDEUVIMED entdecken
Open Access

Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults

Marc E Richmond, Shriprasad R Deshpande, Steven D Zangwill, David P Bichell, Steven J Kindel, William T Mahle, Jacob N Schroder, Mark A Wigger, Kenneth R Knecht, Elfriede Pahl, Nunzio A Gaglianello, Mary A Goetsch und 6 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2023-02 · 165 (2) · 460-468.e2

DOI: 10.1016/j.jtcvs.2022.04.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2023-02. Verfasst von Marc E Richmond und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Cardiology, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY. Electronic…. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Heart Transplantation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Donor-specific cell-free DNA shows promise as a noninvasive marker for allograft rejection, but as yet has not been validated in both adult and pediatric recipients. The study objective was to validate donor fraction cell-free DNA as a noninvasive test to assess for risk of acute cellular rejection and antibody-mediated rejection after heart transplantation in pediatric and adult recipients. METHODS: Pediatric and adult heart transplant recipients were enrolled from 7 participating sites and followed for 12 months or more with plasma samples collected immediately before all endomyocardial biopsies. Donor fraction cell-free DNA was extracted, and quantitative genotyping was performed. Blinded donor fraction cell-free DNA and clinical data were analyzed and compared with a previously determined threshold of 0.14%. Sensitivity, specificity, negative predictive value, positive predictive value, and receiver operating characteristic curves were calculated. RESULTS: A total of 987 samples from 144 subjects were collected. After applying predefined clinical and technical exclusions, 745 samples from 130 subjects produced 54 rejection samples associated with the composite outcome of acute cellular rejection grade 2R or greater and pathologic antibody-mediated rejection 2 or greater and 323 healthy samples. For all participants, donor fraction cell-free DNA at a threshold of 0.14% had a sensitivity of 67%, a specificity of 79%, a positive predictive value of 34%, and a negative predictive value of 94% with an area under the curve of 0.78 for detecting rejection. When analyzed independently, these results held true for both pediatric and adult cohorts at the same threshold of 0.14% (negative predictive value 92% and 95%, respectively). CONCLUSIONS: Donor fraction cell-free DNA at a threshold of 0.14% can be used to assess for risk of rejection after heart transplantation in both pediatric and adult patients with excellent negative predictive value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsHeart TransplantationHumansAdultChildPredictive Value of TestsBiopsyAntibodiesGraft RejectionAllografts

Stichwörter der Autor:innen

cell-free DNAendomyocardial biopsyheart transplantationpediatric heart transplantationrejection

Substanzen

Cell-Free Nucleic AcidsAntibodies

Autor:innen und Institutionen

  • Division of Pediatric Cardiology, Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY. Electronic address: mr2306@cumc.columbia.edu.
  • Division of Pediatric Cardiology, Children's National Heart Institute, Children's National Hospital, Washington, DC.
  • Division of Cardiology, Phoenix Children's Hospital, Phoenix, Ariz.
  • Division of Pediatric Cardiac Surgery, Department of Surgery, Vanderbilt University, Nashville, Tenn.
  • Division of Pediatric Cardiology, Department of Pediatrics, Medical College of Wisconsin, Herma Heart Institute, Children's Wisconsin, Milwaukee, Wis.
  • Division of Cardiology, Department of Pediatrics, Emory University, Children's Healthcare of Atlanta, Atlanta, Ga.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Richmond, M. E., Deshpande, S. R., Zangwill, S. D., Bichell, D. P., Kindel, S. J., Mahle, W. T., Schroder, J. N., Wigger, M. A., Knecht, K. R., Pahl, E., Gaglianello, N. A., Goetsch, M. A., Simpson, P., Dasgupta, M., Zhang, L., North, P. E., Tomita-Mitchell, A., & Mitchell, M. E. (2023). Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults. The Journal of Thoracic and Cardiovascular Surgery, 165(2), 460-468.e2. https://doi.org/10.1016/j.jtcvs.2022.04.027

Vancouver

Richmond ME, Deshpande SR, Zangwill SD, Bichell DP, Kindel SJ, Mahle WT, et al. Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults. The Journal of Thoracic and Cardiovascular Surgery. 2023;165(2):460-468.e2. doi:10.1016/j.jtcvs.2022.04.027

BibTeX
@article{Richmond2023,
  author = {Richmond, Marc E and Deshpande, Shriprasad R and Zangwill, Steven D and Bichell, David P and Kindel, Steven J and Mahle, William T and Schroder, Jacob N and Wigger, Mark A and Knecht, Kenneth R and Pahl, Elfriede and Gaglianello, Nunzio A and Goetsch, Mary A and Simpson, Pippa and Dasgupta, Mahua and Zhang, Liyun and North, Paula E and Tomita-Mitchell, Aoy and Mitchell, Michael E},
  title = {Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2023},
  volume = {165},
  number = {2},
  pages = {460--468.e2},
  doi = {10.1016/j.jtcvs.2022.04.027}
}
Kostenlos starten →